Another brilliant post Hottod - I knew about the 14 exploratory efficacy outcomes but when I saw it in writing, it made me double take as it seems like significantly more than I recalled. It really is quite ambitious and as you say, nicely sets up Neuren for an autism play.
I know this thread is not designed to talk about SP but considering most brokers value us at circa $20, based on Daybue for Retts with a prevalence of 1:10,000 in the US, consider what we might be valued at if we were to successfully treat (even partially) autism, associated spectrum disorders and other neurodevelopmental disorders, with autism having a prevalence rate of 1:36 in the US based on CDC data.
The mind boggles from an investment point of view and the heart warms knowing lots and lots of people could get much needed help.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)